SELLAS spotlights Phase 2 SLS009 combo data with 57% ORR in TP53-mutated AML ahead of ASH 2026
Market Chameleon (Wed, 4-Nov 9:42 AM)
SELLAS hits the 80th event in its Phase 3 REGAL AML study, setting up a final analysis this quarter
Market Chameleon (Wed, 28-Oct 9:15 AM)
Market Chameleon (Mon, 28-Sep 8:39 AM)
SLS Draws Investor Lawsuit Scrutiny After Phase 3 GPS Trial Timing Questions
Market Chameleon (Fri, 18-Sep 11:48 AM)
Strong Cash Position Supports SELLAS as GPS and SLS009 Progress Toward Major Clinical Milestones
Market Chameleon (Wed, 12-Aug 9:12 AM)
